Your browser is no longer supported. Please, upgrade your browser.
Zomedica Corp.
Index- P/E- EPS (ttm)-0.08 Insider Own4.42% Shs Outstand550.54M Perf Week-16.29%
Market Cap1.67B Forward P/E- EPS next Y-0.01 Insider Trans-0.02% Shs Float525.98M Perf Month88.81%
Income-15.60M PEG- EPS next Q0.00 Inst Own6.80% Short Float10.85% Perf Quarter1283.69%
Sales- P/S- EPS this Y-4.50% Inst Trans84.38% Short Ratio0.32 Perf Half Y1365.93%
Book/sh0.08 P/B23.13 EPS next Y75.00% ROA-63.30% Target Price1.20 Perf Year810.88%
Cash/sh0.06 P/C32.18 EPS next 5Y- ROE-159.30% 52W Range0.06 - 2.91 Perf YTD702.25%
Dividend- P/FCF- EPS past 5Y-28.50% ROI- 52W High-36.43% Beta0.92
Dividend %- Quick Ratio25.60 Sales past 5Y- Gross Margin- 52W Low2845.86% ATR0.30
Employees28 Current Ratio25.60 Sales Q/Q- Oper. Margin- RSI (14)52.71 Volatility18.97% 17.47%
OptionableNo Debt/Eq0.05 EPS Q/Q65.60% Profit Margin- Rel Volume0.40 Prev Close2.05
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume177.68M Price1.85
Recom2.00 SMA20-1.41% SMA5072.33% SMA200391.48% Volume71,279,084 Change-9.76%
Feb-18-21 10:16AM  
Feb-16-21 12:02PM  
Feb-12-21 11:03AM  
Feb-11-21 12:18PM  
Feb-09-21 08:16AM  
Feb-08-21 11:00PM  
Feb-05-21 04:09PM  
Feb-01-21 01:03PM  
Jan-25-21 06:10AM  
Jan-18-21 06:15AM  
Jan-15-21 06:23PM  
Jan-12-21 05:53PM  
Jan-04-21 06:10AM  
Dec-15-20 08:53AM  
Dec-07-20 06:01AM  
Nov-28-20 08:50PM  
Nov-18-20 12:38PM  
Nov-13-20 06:00AM  
Nov-12-20 06:30AM  
Oct-26-20 09:25AM  
Oct-02-20 05:05PM  
Sep-25-20 11:00AM  
Sep-14-20 05:44PM  
Sep-10-20 06:55AM  
Sep-08-20 06:55AM  
Aug-27-20 06:55AM  
Aug-10-20 04:15PM  
Aug-07-20 06:55AM  
Aug-03-20 06:55AM  
Jul-21-20 04:01PM  
Jul-07-20 04:01PM  
Jul-01-20 10:30PM  
Jun-30-20 09:00AM  
Jun-25-20 09:26AM  
Jun-16-20 06:05PM  
May-29-20 04:05PM  
May-26-20 10:16PM  
May-20-20 04:05PM  
May-11-20 06:55PM  
Apr-21-20 06:55AM  
Apr-13-20 07:15PM  
Apr-07-20 11:32PM  
Feb-26-20 05:25PM  
Feb-14-20 04:15PM  
Feb-12-20 08:43AM  
Feb-11-20 06:55AM  
Jan-30-20 06:55AM  
Jan-23-20 06:55AM  
Jan-20-20 06:55AM  
Dec-23-19 04:00PM  
Dec-03-19 06:55AM  
Nov-13-19 06:55AM  
Nov-12-19 04:53PM  
Nov-05-19 04:15PM  
Oct-31-19 06:55AM  
Oct-03-19 11:27AM  
Oct-01-19 09:17AM  
Sep-18-19 01:39PM  
Sep-17-19 06:55AM  
Sep-11-19 09:09AM  
Sep-03-19 06:55AM  
Aug-19-19 06:55AM  
Aug-13-19 08:00AM  
Aug-08-19 04:08PM  
Aug-07-19 06:55AM  
Jul-25-19 06:55AM  
Jul-17-19 06:55AM  
Jun-26-19 10:05AM  
Jun-13-19 06:55AM  
Jun-12-19 04:35PM  
Jun-10-19 06:00AM  
May-21-19 06:55AM  
May-10-19 05:21PM  
Mar-26-19 06:00AM  
Mar-25-19 04:01PM  
Mar-05-19 06:55AM  
Feb-26-19 04:05PM  
Jan-15-19 06:55AM  
Jan-14-19 06:55AM  
Dec-20-18 05:23PM  
Dec-19-18 06:00AM  
Nov-28-18 09:53AM  
Nov-27-18 06:51AM  
Nov-26-18 07:25AM  
Nov-13-18 04:47PM  
Nov-12-18 04:30PM  
Oct-16-18 09:00AM  
Sep-18-18 06:55AM  
Aug-15-18 04:15PM  
Aug-09-18 04:01PM  
Jun-28-18 08:57PM  
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACLEOD CHRISTOPHER ROSSDirectorFeb 03Sale1.106,4007,0470Feb 05 04:45 PM
POWERS JOHNNY DDirectorJul 07Buy0.16625,000100,000625,000Jul 07 04:53 PM